Advances in the treatment of lupus nephritis.

  • Zimmerman R
  • Radhakrishnan J
  • Valeri A
 et al. 
  • 4


    Mendeley users who have this article in their library.
  • 58


    Citations of this article.


Systemic lupus erythematosus (SLE) is an autoimmune disease that leads to the formation and deposition of immune complexes throughout the body, which are pathogenic for the disease. Different forms of glomerulonephritis can occur in patients with SLE and can contribute significantly to the associated morbidity and, ultimately, mortality from the disease. Over the past two decades, there have been significant strides in our understanding of the disease and in treatments that attempt to control the formation and deposition of anti-DNA auto-antibodies and immune complexes, as well as the subsequent inflammatory cascade mediated through various cellular and humoral pathways leading to progressive renal damage and end-stage renal disease. In this chapter, we review the current understanding of the pathogenesis and treatment of lupus nephritis in its various stages and discuss the experimental and human data regarding some of the potential newer forms of therapy. We discuss data regarding the use of steroids, azathioprine, cyclophosphamide, cyclosporine A, mycophenolate mofetil, gammaglobulin, plasmapheresis, LJP 394, flaxseed oil, bindarit, anti-CD40 ligand, and CTLA4Ig.

Author-supplied keywords

  • 0000153907
  • 01
  • 10
  • 1227
  • 2005
  • 43563
  • 537-545
  • com
  • doi
  • ff
  • glycerol rhizotomy
  • multiple sclerosis
  • neu
  • neurosurgery 56
  • neurosurgery-online
  • tic douloureux
  • trigeminal neuralgia
  • www

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • R Zimmerman

  • J Radhakrishnan

  • A Valeri

  • G Appel

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free